文献速递心力衰竭与心肌病

肌节蛋白基因突变携带者肥厚型心肌病的外显率

Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

该回顾性分析纳入285例经家系筛查首次未达肥厚型心肌病(HCM)诊断标准的肌节蛋白基因突变携带者,中位随访8.0年,30.2%进展为HCM,15年估计外显率46%(95%CI 38%-54%)。男性及心电图异常为独立预测因素,TNNI3变异风险最低,建议长期筛查中考虑定期心脏磁共振。

要点

  • 肌节蛋白基因突变携带者首次筛查阴性后15年HCM外显率约46%。
  • 男性及心电图异常是进展为HCM的独立预测因素。
  • TNNI3变异携带者进展风险显著低于MYBPC3变异者。

核心结论

  • 首次筛查阴性的肌节蛋白基因突变携带者,随访15年约50%进展为HCM。
  • 男性及心电图异常与HCM进展风险升高独立相关,TNNI3变异风险最低。

研究设计与样本

  • 回顾性分析纳入285例来自156个家系的成人和儿童肌节蛋白基因突变携带者,首次评估未满足HCM诊断标准。
  • 中位年龄14.2岁(四分位距6.8-31.6岁),男性141例(49.5%),145例(50.9%)接受了心脏磁共振(CMR)检查。
  • 中位随访8.0年(四分位距4.0-13.3年)。

主要发现

  • 86例(30.2%)患者进展为HCM;50例中有16例(32.0%)通过CMR而非超声心动图满足诊断标准。
  • 15年随访时HCM估计外显率为46%(95%CI 38%-54%)。
  • 多变量模型调整年龄并按CMR分层后,男性(HR 2.91;95%CI 1.82-4.65)和心电图异常(HR 4.02;95%CI 2.51-6.44)为HCM进展的独立预测因素。
  • 与MYBPC3相比,TNNI3变异风险最低(HR 0.19;95%CI 0.07-0.55)。

临床怎么用

  • 对肌节蛋白基因突变携带者首次筛查阴性后仍需长期规律随访。
  • 长期筛查中应考虑定期进行心脏磁共振检查。
  • 男性或心电图异常携带者可能需更密切监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Predictive genetic screening of relatives of patients with hypertrophic cardiomyopathy (HCM) caused by sarcomere protein (SP) gene mutations is current standard of care, but there are few data on long-term outcomes in mutation carriers without HCM. OBJECTIVES: The aim of this study was to determine the incidence of new HCM diagnosis in SP mutation carriers. METHODS: This was a retrospective analysis of adult and pediatric SP mutation carriers identified during family screening who did not fulfill diagnostic criteria for HCM at first evaluation. RESULTS: The authors evaluated 285 individuals from 156 families (median age 14.2 years [interquartile range: 6.8 to 31.6 years], 141 [49.5%] male individuals); 145 (50.9%) underwent cardiac magnetic resonance (CMR). Frequency of causal genes was as follows: MYBPC3 n = 123 (43.2%), MYH7 n = 69 (24.2%), TNNI3 n = 39 (13.7%), TNNT2 n = 34 (11.9%), TPM1 n = 9 (3.2%), MYL2 n = 6 (2.1%), ACTC1 n = 1 (0.4%), multiple mutations n = 4 (1.4%). Median follow-up was 8.0 years (interquartile range: 4.0 to 13.3 years) and 86 (30.2%) patients developed HCM; 16 of 50 (32.0%) fulfilled diagnostic criteria on CMR but not echocardiography. Estimated HCM penetrance at 15 years of follow-up was 46% (95% confidence interval [CI]: 38% to 54%). In a multivariable model adjusted for age and stratified for CMR, independent predictors of HCM development were male sex (hazard ratio [HR]: 2.91; 95% CI: 1.82 to 4.65) and abnormal electrocardiogram (ECG) (HR: 4.02; 95% CI: 2.51 to 6.44); TNNI3 variants had the lowest risk (HR: 0.19; 95% CI: 0.07 to 0.55, compared to MYBPC3). CONCLUSIONS: Following a first negative screening, approximately 50% of SP mutation carriers develop HCM over 15 years of follow-up. Male sex and an abnormal ECG are associated with a higher risk of developing HCM. Regular CMR should be considered in long-term screening.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lorenzini M, Norrish G, Field E, et al. Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers. J Am Coll Cardiol. 2020. PMID: 32731933. doi:10.1016/j.jacc.2020.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。